Damora Therapeutics Inc (DMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -209,839 | -21,439 | -38,349 | -61,624 | -51,752 |
| Depreciation Amortization | 22 | 91 | -162 | 608 | 1,092 |
| Accounts payable and accrued liabilities | 17,272 | -1,325 | -1,648 | 1,819 | -1,320 |
| Other Working Capital | 18,364 | -2,667 | -4,370 | 11,937 | -6,624 |
| Other Operating Activity | 167,455 | 6,717 | 7,618 | 4,328 | 6,296 |
| Operating Cash Flow | $-6,726 | $-18,623 | $-36,911 | $-42,932 | $-52,308 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | -25,937 | -44,865 | -84,209 |
| PPE Investments | N/A | N/A | 83 | -196 | -223 |
| Net Acquisitions | -17,374 | N/A | N/A | N/A | N/A |
| Sale Of Investment | N/A | 11,650 | 48,184 | 57,445 | 36,384 |
| Investing Cash Flow | $-17,374 | $11,650 | $22,330 | $12,384 | $-48,048 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 33 | N/A | 2,876 | 507 | N/A |
| Other Financing Activity | 266,811 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $266,844 | $N/A | $2,876 | $507 | $N/A |
| Exchange Rate Effect | 705 | -317 | 384 | 264 | -917 |
| Beginning Cash Position | 14,175 | 21,465 | 32,786 | 62,563 | 163,836 |
| End Cash Position | 257,624 | 14,175 | 21,465 | 32,786 | 62,563 |
| Net Cash Flow | $243,449 | $-7,290 | $-11,321 | $-29,777 | $-101,273 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,726 | -18,623 | -36,911 | -42,932 | -52,308 |
| Capital Expenditure | N/A | N/A | N/A | -196 | -223 |
| Free Cash Flow | -6,726 | -18,623 | -36,911 | -43,128 | -52,531 |